{"id":"sintilimab-plus-platinum-based-chemotherapy","safety":{"commonSideEffects":["Nausea","Fatigue","Decreased appetite","Anemia","Neutropenia","Immune-related adverse events"]},"_chembl":{"chemblId":"CHEMBL4297829","moleculeType":"Antibody"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"PD-1","explanation":"Sintilimab is a monoclonal antibody that binds to PD-1 receptors on T cells, blocking the PD-1/PD-L1 pathway and restoring anti-tumor immune responses. Platinum-based chemotherapy agents cause DNA crosslinking and damage in rapidly dividing cancer cells. The combination aims to provide synergistic anti-tumor activity through immune activation and direct cytotoxicity.","oneSentence":"Sintilimab blocks PD-1 receptor to restore immune response against cancer cells while platinum agents damage tumor DNA."},"_scrapedAt":"2026-03-28T01:34:45.267Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122764,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"pembrolizumab plus chemotherapy","brand":"Keytruda","company":"Merck","rationale":"Anti-PD-1 antibody combined with chemotherapy for similar indications"},{"name":"nivolumab plus chemotherapy","brand":"Opdivo","company":"Bristol Myers Squibb","rationale":"Anti-PD-1 antibody combined with chemotherapy for cancer treatment"},{"name":"atezolizumab plus chemotherapy","brand":"Tecentriq","company":"Roche","rationale":"Anti-PD-L1 antibody combined with chemotherapy for various cancers"}],"description":"Sintilimab plus platinum-based chemotherapy is an investigational combination therapy being studied in Phase 3 trials. Sintilimab is an anti-PD-1 monoclonal antibody combined with standard platinum-containing chemotherapy regimens for the treatment of various cancers.","indications":{"approved":[{"status":"investigational","condition":"Non-small cell lung cancer","patientPopulation":"Adult, first-line or subsequent therapy"},{"status":"investigational","condition":"Esophageal squamous cell carcinoma","patientPopulation":"Adult, first-line therapy"},{"status":"investigational","condition":"Gastric cancer","patientPopulation":"Adult, first-line therapy"}]},"trialDetails":[{"nctId":"NCT07138755","phase":"PHASE2","title":"The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients","status":"RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2025-08-29","conditions":"NSCLC, Sintilimab, Adaptive Radiotherapy","enrollment":35},{"nctId":"NCT07492342","phase":"PHASE2","title":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","status":"RECRUITING","sponsor":"Jianxing He","startDate":"2026-01-29","conditions":"Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC","enrollment":30},{"nctId":"NCT07459296","phase":"PHASE3","title":"Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC","status":"RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2026-03-05","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":266},{"nctId":"NCT06775743","phase":"PHASE2","title":"ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-01-15","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer","enrollment":53},{"nctId":"NCT07400302","phase":"PHASE2","title":"Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery","status":"RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2026-02-01","conditions":"Mucosal Melanoma, PD-L1 Positive","enrollment":220},{"nctId":"NCT07005336","phase":"PHASE2","title":"A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"TJ Biopharma Co., Ltd.","startDate":"2025-01-09","conditions":"Non Small Cell Lung Cancer","enrollment":150},{"nctId":"NCT07371611","phase":"PHASE3","title":"Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Qunxing Li,MD","startDate":"2026-01-01","conditions":"Locally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC)","enrollment":104},{"nctId":"NCT07309952","phase":"PHASE2","title":"Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Yang Hong","startDate":"2025-12-31","conditions":"Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer","enrollment":28},{"nctId":"NCT06703398","phase":"PHASE2","title":"A Study of GC101 TIL in Advanced Melanoma","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2024-12-20","conditions":"Melanoma","enrollment":98},{"nctId":"NCT06121505","phase":"PHASE2","title":"Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-03-01","conditions":"Lung Squamous Cell Carcinoma","enrollment":114},{"nctId":"NCT06281964","phase":"PHASE3","title":"Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.","status":"ENROLLING_BY_INVITATION","sponsor":"Avistone Biotechnology Co., Ltd.","startDate":"2023-12-01","conditions":"Non-Small-Cell Lung Cancer","enrollment":327},{"nctId":"NCT07088731","phase":"PHASE2","title":"Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-09","conditions":"Cervical Carcinoma","enrollment":180},{"nctId":"NCT06896422","phase":"PHASE1","title":"Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2025-06-01","conditions":"Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody","enrollment":80},{"nctId":"NCT07061535","phase":"PHASE2","title":"Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08-01","conditions":"Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer","enrollment":40},{"nctId":"NCT05116462","phase":"PHASE3","title":"Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2024-03-15","conditions":"Non-Small Cell Lung Cancer","enrollment":506},{"nctId":"NCT05357846","phase":"PHASE3","title":"PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-11-01","conditions":"Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer","enrollment":422},{"nctId":"NCT04548440","phase":"PHASE2","title":"Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients","status":"COMPLETED","sponsor":"Sun Yat-Sen University Cancer Center","startDate":"2020-08-31","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT06962189","phase":"PHASE2","title":"The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2025-05-15","conditions":"Non Small Cell Lung Cancer (Stage III)","enrollment":39},{"nctId":"NCT06956716","phase":"PHASE1, PHASE2","title":"Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-04-09","conditions":"Advanced Intrahepatic Cholangiocarcinoma","enrollment":30},{"nctId":"NCT04836728","phase":"PHASE2","title":"Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-03-31","conditions":"Non-small Cell Lung Cancer Metastatic, First-line Treatment","enrollment":156},{"nctId":"NCT06494943","phase":"PHASE1, PHASE2","title":"Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-06-26","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma","enrollment":27},{"nctId":"NCT06837948","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-02-18","conditions":"Locally Advanced Non-Small Cell Lung Cancer","enrollment":160},{"nctId":"NCT06714708","phase":"PHASE2","title":"Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC","status":"RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2024-11-20","conditions":"NSCLC, Neoadjuvant Immunotherapy, Low Dose Radiotherapy","enrollment":86},{"nctId":"NCT05504278","phase":"PHASE1","title":"Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-09-20","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":144},{"nctId":"NCT06730373","phase":"PHASE2","title":"First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-10-17","conditions":"HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma","enrollment":110},{"nctId":"NCT06718205","phase":"PHASE2","title":"Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2023-03-08","conditions":"Esophageal Cancer","enrollment":112},{"nctId":"NCT05979818","phase":"PHASE1","title":"Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2024-11-13","conditions":"Non Small Cell Lung Cancer, Propranolol","enrollment":6},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT06604351","phase":"PHASE2","title":"Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction","status":"NOT_YET_RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2024-09-15","conditions":"Non-Small Cell Lung Cancer","enrollment":39},{"nctId":"NCT05849246","phase":"PHASE2","title":"The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)","status":"TERMINATED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-07-31","conditions":"Non-squamous Non-small-cell Lung Cancer","enrollment":4},{"nctId":"NCT06543069","phase":"PHASE2","title":"Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-01-31","conditions":"Malignant Peritoneal Mesothelioma, Advanced","enrollment":28},{"nctId":"NCT06138028","phase":"PHASE2, PHASE3","title":"Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer","status":"RECRUITING","sponsor":"Qingdao Central Hospital","startDate":"2023-09-20","conditions":"Metastatic Esophageal Squamous Cell Carcinoma","enrollment":90},{"nctId":"NCT06295926","phase":"PHASE2","title":"Serplulimab Combined With CCRT for LS-SCLC.","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-04-04","conditions":"Small Cell Lung Cancer","enrollment":96},{"nctId":"NCT06502080","phase":"PHASE2","title":"Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-07","conditions":"Biliary Tract Cancer","enrollment":128},{"nctId":"NCT06485557","phase":"PHASE3","title":"A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-08-01","conditions":"Resectable Non-small Cell Lung Cancer","enrollment":90},{"nctId":"NCT06084897","phase":"PHASE2","title":"Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-10-16","conditions":"Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb","enrollment":120},{"nctId":"NCT06447454","phase":"","title":"Combining Chemoradiotherapy With Sintilimab in First-Line ICC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-07-01","conditions":"ICC","enrollment":19},{"nctId":"NCT06391190","phase":"PHASE1, PHASE2","title":"Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2022-01-01","conditions":"Locally Advanced Cervical Carcinoma, Concurrent Chemoradiotherapy, Immunotherapy","enrollment":20},{"nctId":"NCT04590599","phase":"PHASE2","title":"A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2020-12-08","conditions":"Advanced Cervical Cancer","enrollment":205},{"nctId":"NCT03802240","phase":"PHASE3","title":"Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2019-07-11","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":492},{"nctId":"NCT03748134","phase":"PHASE3","title":"Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2018-12-24","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":746},{"nctId":"NCT06031597","phase":"PHASE3","title":"Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-09-15","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":105},{"nctId":"NCT04728724","phase":"PHASE2","title":"Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2022-09-10","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":100},{"nctId":"NCT05026593","phase":"PHASE1","title":"A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-09-07","conditions":"SCLC","enrollment":60},{"nctId":"NCT05834413","phase":"NA","title":"Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2023-05-01","conditions":"Lung Cancer","enrollment":367},{"nctId":"NCT03700476","phase":"PHASE3","title":"Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-12-21","conditions":"Nasopharyngeal Neoplasms","enrollment":425},{"nctId":"NCT04675983","phase":"PHASE3","title":"A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)","status":"TERMINATED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-03-10","conditions":"Gastric Adenocarcinoma","enrollment":36},{"nctId":"NCT05749042","phase":"PHASE2","title":"A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Xin-Hua Xu","startDate":"2023-01-18","conditions":"Oral Cavity Squamous Cell Carcinoma","enrollment":70},{"nctId":"NCT03629925","phase":"PHASE3","title":"Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2018-09-28","conditions":"Squamous NSCLC","enrollment":357},{"nctId":"NCT04872582","phase":"PHASE2","title":"Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study","status":"UNKNOWN","sponsor":"XIANG YANQUN","startDate":"2021-07-29","conditions":"Metastatic Nasopharyngeal Carcinoma, Chemotherapy Effect","enrollment":33},{"nctId":"NCT05648071","phase":"PHASE3","title":"First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2021-12-01","conditions":"Advanced Non-squamous Non-Small-Cell Lung Cancer","enrollment":60},{"nctId":"NCT03574402","phase":"PHASE2","title":"Phase II Umbrella Study Directed by Next Generation Sequencing","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2018-07-09","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":400},{"nctId":"NCT04861948","phase":"PHASE1","title":"IBI188 Combination Therapy in Solid Tumors","status":"TERMINATED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-05-25","conditions":"Solid Tumors, Lung Adenocarcinoma, Osteosarcoma","enrollment":9},{"nctId":"NCT03946969","phase":"PHASE2","title":"Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2019-05-09","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT04625543","phase":"PHASE2","title":"Neoadjuvant Immunotherapy to ESCC","status":"WITHDRAWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2020-12","conditions":"Esophagus SCC","enrollment":""},{"nctId":"NCT04144582","phase":"PHASE2","title":"Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Yongchang Zhang","startDate":"2019-01-01","conditions":"Non-small Cell Lung Cancer","enrollment":30},{"nctId":"NCT03798743","phase":"PHASE2","title":"Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study","status":"COMPLETED","sponsor":"Hunan Province Tumor Hospital","startDate":"2019-01-01","conditions":"Non-small Cell Lung Cancer","enrollment":30},{"nctId":"NCT05105672","phase":"PHASE2","title":"A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2021-03-08","conditions":"Uterine Cervical Neoplasms, Sintilimab","enrollment":20},{"nctId":"NCT05136768","phase":"PHASE2","title":"Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC)","status":"UNKNOWN","sponsor":"Jun-Lin Yi, MD","startDate":"2021-12","conditions":"Head and Neck Squamous Cell Carcinoma, Metastases, Immunotherapy","enrollment":50},{"nctId":"NCT05008861","phase":"PHASE1","title":"Gut Microbiota Reconstruction for NSCLC Immunotherapy","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-09-01","conditions":"Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT04846452","phase":"PHASE2","title":"Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-06-01","conditions":"Metastatic NSCLC, Recurrent NSCLC, Advanced Non-Small Cell Squamous Lung Cancer","enrollment":40},{"nctId":"NCT04769076","phase":"PHASE2","title":"The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2021-03-01","conditions":"Nasopharyngeal Carcinoma","enrollment":40},{"nctId":"NCT04513301","phase":"PHASE2","title":"Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study","status":"UNKNOWN","sponsor":"Shanghai Cancer Hospital, China","startDate":"2020-01-01","conditions":"Lung Neoplasms","enrollment":70},{"nctId":"NCT04300959","phase":"PHASE2","title":"Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2020-01-01","conditions":"Biliary Tract Cancer","enrollment":80},{"nctId":"NCT04252365","phase":"PHASE2","title":"Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2020-03-01","conditions":"Nsclc","enrollment":20},{"nctId":"NCT04189094","phase":"PHASE2","title":"Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2020-01-01","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":140},{"nctId":"NCT04124731","phase":"PHASE2","title":"Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2019-10","conditions":"Carcinoma, Non-small Cell Lung Cancer","enrollment":98},{"nctId":"NCT03619824","phase":"PHASE2","title":"PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-01","conditions":"Nasopharyngeal Neoplasms","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Group A","Group B","Group C"],"phase":"phase_3","status":"active","brandName":"sintilimab plus platinum-based chemotherapy","genericName":"sintilimab plus platinum-based chemotherapy","companyName":"Tang-Du Hospital","companyId":"tang-du-hospital","firstApprovalDate":"","aiSummary":"Sintilimab, a programmed cell death protein 1 antagonist antibody, is being studied in combination with platinum-based chemotherapy for the treatment of advanced non-small cell lung cancer. This combination is being investigated as a neoadjuvant therapy in a clinical trial, specifically in patients with stage II-III non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}